Welcome to our dedicated page for Eiger BioPharmaceuticals news (Ticker: EIGR), a resource for investors and traders seeking the latest updates and insights on Eiger BioPharmaceuticals stock.
Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) is a clinical-stage biopharmaceutical company focused on developing therapies for rare diseases. This dedicated news hub provides investors and industry observers with timely updates on corporate developments, research milestones, and strategic initiatives.
Our curated collection features official press releases, regulatory filings, and clinical trial progress reports. Key areas of coverage include therapeutic pipeline updates, partnership announcements, and details regarding the company’s ongoing restructuring process under Chapter 11 protection.
Users will find essential information about Eiger’s asset management strategies, including potential licensing agreements and court-supervised sales of clinical-stage therapies. The repository maintains neutral reporting on financial repositioning efforts while highlighting scientific advancements in hepatitis delta virus (HDV) and other rare disease research programs.
Bookmark this page for streamlined access to verified updates about EIGR’s operational changes and research developments. Check regularly for new information about therapeutic candidate evaluations, strategic partnerships, and restructuring milestones that shape the company’s trajectory in biopharmaceutical innovation.
Eiger BioPharmaceuticals (Nasdaq:EIGR) announced the sale of its Priority Review Voucher (PRV) for $95 million. Eiger will receive 50% of the proceeds, totaling $47.5 million, as per its agreement with The Progeria Research Foundation. The PRV was granted following the FDA approval of Zokinvy™ (lonafarnib) for Progeria treatment. This sale provides Eiger with non-dilutive capital, enhancing its balance sheet and allowing better access to Zokinvy for affected children globally. The transaction is subject to standard closing conditions.
Eiger BioPharmaceuticals has received FDA approval for ZokinvyTM (lonafarnib), the first treatment for Hutchinson-Gilford Progeria Syndrome (HGPS) and processing-deficient Progeroid Laminopathies. This groundbreaking therapy demonstrated a 60% reduction in mortality and extended average survival by 2.5 years in treated patients. With an identified patient population of approximately 20 in the U.S., Eiger plans to sell the Rare Pediatric Disease Priority Review Voucher awarded by the FDA. The drug's commercial launch is a significant milestone for both Eiger and the Progeria community.
Eiger BioPharmaceuticals (Nasdaq:EIGR) announced positive results from the Phase 2 LIFT study, evaluating the combination of Peginterferon lambda and Lonafarnib for treating chronic Hepatitis Delta Virus (HDV). The study involved 26 adult patients, with 77% achieving a >2 log decline in HDV RNA at Week 24. At Week 48, 55% showed improvement in the Histology Activity Index. Adverse effects were mostly mild to moderate. Lambda and Lonafarnib are both investigational agents, with ongoing regulatory designations. Upcoming milestones include a PDUFA date for Hutchinson-Gilford Progeria Syndrome on November 20, 2020.
Eiger BioPharmaceuticals (Nasdaq: EIGR) announced the presentation of two case studies from its Phase 2 LIMT trial at The Liver Meeting Digital Experience™ 2020. This study involved 33 patients treated with Peginterferon lambda for chronic hepatitis delta virus (HDV) infection. Results showed a 36% durable virologic response at 24 weeks post-treatment and significant liver fibrosis regression in two patients. The most common side effects were mild to moderate flu-like symptoms. Eiger continues to develop Lambda, moving towards Phase 3 trials.
Eiger BioPharmaceuticals (Nasdaq:EIGR) announced its participation in two investor conferences in November 2020. The first event is the Stifel Virtual Healthcare Conference on November 18, where Eiger will present from 2:00-2:30 PM ET. The second is the Jefferies Virtual London Healthcare Conference on November 19, with Eiger's presentation scheduled from 6:10-6:40 PM GMT. Live webcasts will be available on the Eiger website. Eiger focuses on treatments for serious rare diseases, including Hepatitis Delta Virus.
Eiger BioPharmaceuticals (Nasdaq:EIGR) reported its Q3 2020 financial results, revealing a net loss of $15.7 million, or $0.52 per share, an improvement from a $18.6 million loss, or $0.76 per share in Q3 2019. Cash reserves totaled $125.3 million. R&D expenses decreased to $9.8 million, down from $14.1 million in the previous year, while G&A expenses rose to $5.0 million from $4.2 million. Upcoming milestones include a PDUFA target date of November 20, 2020 for Zokinvy and full enrollment of the Phase 3 D-LIVR study in 2021.
Eiger BioPharmaceuticals (Nasdaq:EIGR) announced data from its Hepatitis Delta Virus (HDV) programs, featured in three abstracts for The Liver Meeting Digital Experience™ (November 13-16, 2020). The presentations include a Phase 2 study of Peginterferon Lambda, results highlighting noninvasive tests for liver cirrhosis, and regression of liver fibrosis after therapy. Peginterferon Lambda is positioned for Phase 3 development, receiving FDA Orphan Designation and Breakthrough Designation. Lonafarnib, also in Phase 3 trials and with similar designations, aims to address unmet needs in HDV treatment.
Eiger BioPharmaceuticals (Nasdaq: EIGR) reported positive results from the ILIAD Study, testing Peginterferon Lambda in outpatients with mild to moderate COVID-19. In a randomized trial involving 60 patients, Lambda demonstrated a significantly greater decline in SARS-CoV-2 viral load compared to placebo, especially in patients with high baseline viral loads. By Day 7, 80% of Lambda-treated patients were negative for the virus, leading to a median clearance time of 7 days. Lambda was well-tolerated with minimal adverse effects. The study is part of ongoing research evaluating Lambda's efficacy against COVID-19.
Eiger BioPharmaceuticals (Nasdaq:EIGR) announced results from an investigator-sponsored study evaluating Peginterferon Lambda-1a (Lambda) for treating mild COVID-19. The study, involving 120 patients, showed no significant difference in viral shedding or symptom resolution compared to placebo, with both groups ceasing viral shedding within a median of 7 days. Lambda was well-tolerated, with minimal adverse events. Eiger is advancing Lambda for Hepatitis Delta Virus, having secured FDA and EMA concurrence on a Phase 3 study.
Eiger BioPharmaceuticals (Nasdaq:EIGR) announced participation in four investor conferences in September 2020. Highlights include:
- Panels at Citi's 15th Annual BioPharma Conference on September 9, discussing COVID-19 Therapeutics and Rare Disease Drug Development.
- A corporate update at the Baird Global Healthcare Conference on September 9.
- Participation in the H.C. Wainwright Annual Global Investment Conference from September 14-16.
- A corporate update at the Cantor Global Virtual Healthcare Conference on September 17.
Live webcasts will be available on Eiger's website.
FAQ
What is the market cap of Eiger BioPharmaceuticals (EIGR)?
